Werewolf Therapeutics (HOWL) investor relations material

Executive summary

• Focused on developing conditionally activated immunotherapies for cancer using the proprietary PREDATOR platform, with lead candidates WTX-124 and WTX-330 in clinical trials; WTX-124 received FDA Fast Track Designation for advanced melanoma.

• WTX-124 is in Phase 1/1b trials as monotherapy and in combination with pembrolizumab; all expansion arms are enrolling or fully enrolled, with enrollment completion expected by Q1 2026.

• WTX-330 is in Phase 1b/2 for advanced solid tumors, with updates expected in Q4 2025.

• IND-enabling studies for WTX-1011, a T-cell engager targeting STEAP1, are ongoing, with candidate nomination anticipated by year-end 2025.

• No products approved for sale; all revenue to date from a collaboration with Jazz Pharmaceuticals, which has now concluded all material performance obligations.

Financial highlights

• Cash and cash equivalents were $65.7 million as of September 30, 2025, down from $111.0 million at December 31, 2024, and $77.6 million at June 30, 2025.

• No revenue recognized in the nine months ended September 30, 2025, compared to $1.9 million in the same period in 2024; collaboration revenue for Q3 2025 was $1.9 million.

• Net loss of $16.4 million for Q3 2025 and $52.4 million for the nine months ended September 30, 2025, compared to $16.7 million and $50.1 million in the prior year periods.

• Research and development expenses were $11.6 million for Q3 2025 and $37.9 million for the nine months, both down from prior year periods.

• General and administrative expenses were $4.1 million for Q3 2025 and $13.4 million for the nine months, both lower year-over-year.

Outlook and guidance

• Cash and cash equivalents are insufficient to fund operations for at least twelve months according to one source, but another projects the cash runway into Q4 2026.

• Interim data and regulatory feedback for WTX-124 and WTX-330 expected in Q4 2025, guiding future registrational pathways.

• Nomination of a differentiated WTX-1011 candidate anticipated by year-end 2025.

• Evaluating options for additional public equity financing, collaborations, or licensing to secure funding.